Literature DB >> 9668737

Seropositive, symmetric polyarthritis in a patient with poorly differentiated lung carcinoma: carcinomatous polyarthritis, hypertrophic osteoarthropathy, or rheumatoid arthritis?

Y Farhey1, M Luggen.   

Abstract

Polyarthritis resembling rheumatoid arthritis (RA) may be the presenting manifestation of occult malignancy. Hypertrophic osteoarthropathy (HOA) may also develop in association with pulmonary neoplasia and consists of clubbing, periostitis, and arthropathy. We describe a patient who presented with a seropositive, symmetric, inflammatory polyarthritis only 4 weeks before a lung tumor became clinically and radiographically apparent. After initiation of chemotherapy, she developed features characteristic of HOA. It appears that the patient had both RA and HOA. We discuss the differential diagnosis and review the relationship of RA, HOA, carcinomatous polyarthritis, and malignancy.

Entities:  

Mesh:

Year:  1998        PMID: 9668737     DOI: 10.1002/art.1790110210

Source DB:  PubMed          Journal:  Arthritis Care Res        ISSN: 0893-7524


  4 in total

Review 1.  Migratory polyarthritis as a paraneoplastic syndrome.

Authors:  Melanie Zupancic; Ani Annamalai; Jennifer Brenneman; Sriya Ranatunga
Journal:  J Gen Intern Med       Date:  2008-09-23       Impact factor: 5.128

2.  Migratory polyarthritis as a paraneoplastic syndrome in a patient with diffuse large B cell lymphoma: a case report.

Authors:  Kavinga Kalhari Kobawaka Gamage; Mohomed Ismail Mohomed Rifath; Harshini Fernando
Journal:  J Med Case Rep       Date:  2018-06-26

3.  SAPHO Syndrome Masquerading as Metastatic Breast Cancer.

Authors:  Devin Malik; Richa Handa; Andrew Petraszko; Sheela Tejwani
Journal:  Case Rep Rheumatol       Date:  2018-03-20

Review 4.  Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literature.

Authors:  Francesco Bozzao; Stella Bernardi; Franca Dore; Lorenzo Zandonà; Fabio Fischetti
Journal:  BMC Musculoskelet Disord       Date:  2018-05-14       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.